Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Request for Pharmacist

 
Establishing/Expanding MediTrack system for pharmaceutical products
Terms of Reference: Pharmacist
National E-health Program
 
1- Background

For several years, the Ministry of Public Health (MoPH) has been working on pharmaceutical sector reform, which has positively impacted the quality, safety, and efficacy of pharmaceutical products, as well as Lebanon's overall health status.

In 2018, the MoPH began the process of implementing the National Barcode System in Lebanon by requesting that all registered pharmaceutical importers and local manufacturers who intend to import or produce pharmaceutical products use the 2D Matrix Barcode, as per the standards of the "Global Standards One" GS1, on the outer pack of all registered/under-registration pharmaceutical products. The "MediTrack" pharmaceutical traceability information system was created to connect all stakeholders in the supply chain in a single network and allow them to share information.

Since 2020, the "MediTrack" system has been implemented in all drugstores (around 200) to track imported medications all the way back to the supplier's purchase and distribution.

In 2022, due to the limited budget allocated by the Lebanese central bank for total subsidization of catastrophic illness medications, there is an urgent need to track the dispensing of cancer medications up to the patient level in both the public and private sectors.

In September 2022, a pilot phase was launched to connect hospitals and community pharmacies with WHO support to test the system, evaluate its feasibility, time, and cost, and identify gaps to improve system performance prior to a full-scale project implementation.

The first phase of the project was completed successfully by developing the MediTrack system in accordance with GS1 requirements, testing the software program, and conducting a pilot run with the required stakeholders. MediTrack is now used by 60 hospitals and 180 pharmacies to dispense subsidized catastrophic illness medications to their patients. There are approximately 3800 remaining pharmacies, in addition to the remaining hospitals and PHC centers, that must be linked to MediTrack by 2023.

Following the successful implementation of the NBS at the MOPH with medicine importers and distributors, the MoPH eHealth department launched phase two of the NBS, with WHO support, to achieve the MediTrack goal of tracing all types of medicines all the way up to the patient level.

According to the decision, the inspection department was connected to MediTrack by January 2023, and inspectors began their official role on MediTrack. All imported medications added to MediTrack by importers remain pending until the inspector approves and the products are released to the market.

More than three thousand community pharmacies will be linked to Meditrack, and according to MOPH decree 988, all MOPH registered medications will be distributed to pharmacies through Meditrack beginning in January 2024.

2- Job Description

Under the direct supervision of the Head of the National E-health program (Ms. Lina Abou Mrad), the Pharmacist role is to ensure timely and accurate data related to pharmaceutical products on MoPH data platforms mainly the MediTrack system. The pharmacist will help in establishing rules and procedures for the data validation of pharmaceutical products information systems and will ensure data privacy across MoPH departments and external stakeholders. He/she will also support in the proper implementation at all Meditrack system stakeholders.

3- Job Type

Full Time

4- Work to be Performed.
 
Output 1: Timely and accurately update MediTrack database System through continuous follow-up with pharmacies and health facilities mainly the following tasks:
  • Input non registered medications or donations data into MediTrack.
  • Update the GTIN for the donations and non-registered medications.
  • Update reception data for all donations and non-registered medications on MediTrack (even if products don’t have a 2D barcode).
- Deliverable 1.1: Provide monthly updated number of registered pharmacies through Meditrack on respective database with exchange rates and checking on transactions performed.
- Deliverable 1.2: Provide weekly updated database of from active Meditrack implementers (pharmaceutical companies, manufacturers, importers, wholesalers/distributors)
o Provide monthly status towards reaching the planned targets (ex: number of pharmacies per region connected to the system).
 
Output 2: Conduct visits to Meditrack stakeholders with skills and knowledge to present and respond to inquiries from multiple Meditrack stakeholders.
- Deliverable 2.1: A weekly schedule of visits to community and hospital pharmacies
- Deliverable 2.2: Fill the standard questionnaire , with the ability to respond to inquiries on Meditrack implementation.
- Deliverable 2.3: Report on the status of the Meditrack implementation
 
Output 3: Provide and assist in the training on MediTrack to pharmaceutical companies, hospitals, pharmacies, and all stakeholders.
- Deliverable 3.1: training sessions recording.
- Deliverable 3.2: follow-up with trainees for Meditrack setup and implementation.
 
Output 4: Review pricing and repricing files submitted for local and imported products and calculate the authorized price according to pricing decisions.
- Deliverable 4.1: Review price revisions submitted (for price increase, price decrease, and objections) and provide the accepted authorized price.
- Deliverable 4.2: prepare the drugs pricing Index according to the foreign currency rates provided from BDL.
 
- Perform any other task requested from the Head of the National E-Health Program.
 
5- Specific requirements

Qualifications required: PharmD degree, Master of Science in Pharmacy, or any equivalent degree. Graduates with a bachelor’s degree are eligible if they demonstrate more years of experience.

Experience required:
Essential:Two years’ relevant work experience in pharmaceutical supply chain management. - Proven experience in public related settings. - Lebanese Nationality.
 
Skills / Technical skills and knowledge:
- Strong knowledge of the legal and regulatory frameworks of pharmaceuticals products in Lebanon.
- Proven record of conducting pharmaceutical provision, pharma, and health products management.
- Effective communication, interpersonal and organizational skills.
- General ability to report, draft ideas and concepts, clearly and concisely in written and oral form.
- General ability to research, analyze, evaluate, and synthesize qualitative and quantitative information.
- Computer Skills: Excellent knowledge of Microsoft Office including Word.

Language requirements:
English; Arabic; French (read, write, speak)

6- Place of assignment

Submit your cv to the Ministry of Public Health email address: info@moph.gov.lb 
    ...
    179
ATC Name B/G Ingredients Dosage Form Price
R03AL06 SPIOLTO RESPIMAT B Olodaterol HCl - 2.5mcg/puff, Tiotropium bromide monohydrate - 2.5mcg/puff Inhalation solution 5,087,788 L.L
A06AB58 PICOPREP B Magnesium oxide - 3.5g, Citric acid - 12g, Sodium picosulfate - 10mg Powder 694,767 L.L
D07XC03 ELICASAL G Mometasone furoate - 1mg/g, Salicylic acid - 50mg/g Ointment 462,282 L.L
J07BK01 VARICELLA VACCINE LIVE BioTech Varicella-herpes zoster virus (Oka strain), grown in human diploid cells (SV-cell line), live attenuated - Injectable suspension 3,104,276 L.L
L04AA32 APRIVA STARTER PACK G Apremilast - 10mg, Apremilast - 20mg, Apremilast - 30mg Tablet, film coated 22,154,866 L.L
R03AL11 BREZTRI AEROSPHERE B Formoterol fumarate dihydrate - 5mcg, Glycopyrronium Bromide - 7.2mcg, Budesonide - 160mcg Inhalation suspension 6,705,774 L.L
A06AB58 CITRAFLEET G Sodium picosulfate - 10mg/sachet, Magnesium oxide (light) - 3.5g/sachet, Citric acid (anhydrous) - 10.97g/sachet, Potassium - 195mg/sachet Powder for solution 1,191,988 L.L
D07XC04 TRAVOCORT B Diflucortolone valerate - 0.1%, Isoconazole nitrate - 1% Cream 435,405 L.L
J07BM03 GARDASIL 9 HUMAN PAPILLOMAVIRUS 9- VALENT VACCINE RECOMBINANT B Papillomavirus (human type 6) - 30mcg/0.5ml, Papillomavirus (human type 11) - 40mcg/0.5ml, Papillomavirus (human type 16) - 60mcg/0.5ml, Papillomavirus (human type 18) - 40mcg/0.5ml, Papillomavirus (human type 31) - 20mcg/0.5ml, Papillomavirus (human type 33) - 20mcg/0.5ml, Papillomavirus (human type 45) - 20mcg/0.5ml, Papillomavirus (human type 52) - 20mcg/0.5ml, Papillomavirus (human type 58) - 20mcg/0.5ml Injectable suspension 14,139,396 L.L
D07XC04 AZONIT - D G Diflucortolone valerate - 1mg/g, Isoconazole nitrate - 10mg/g Cream 225,766 L.L
J07CA LANTIGEN B B Streptococcus pneumoniae type 3 (antigenic extracts) - 63.2A.U./ml, Streptococcus pyogenes group A (antigenic extracts) - 126.2A.U./ml, Branhamella catarrhalis (antigenic extracts) - 39.9A.U./ml, Staphylococcus aureus (antigenic extracts) - 79.6A.U./ml, Haemophilus influenzae type b (antigenic extracts) - 50.2A.U./ml, Klebsiella pneumoniae (antigenic extracts) - 39.8A.U./ml Drops suspension 916,501 L.L
D08AC52 CYTEAL Solution Antiseptique G Chlorhexidine digluconate - 0.5ml/100ml, Hexamidine - 0.1g/100ml, Chlorocresol - 0.3g/100ml Solution 362,420 L.L
J07CA02 TETRAXIM (Vaccin Diphterique, tetanique, coquelucheux acellulaire et Poliomyelitique inactivé adsorbé) B Diphteria toxoid purified - ?30IU, Tetanus toxoid purified - ?40IU, Poliomyelitis virus type 1 inactivated - 40D.U., Poliomyelitis virus type 2 inactivated - 8D.U., Poliomyelitis virus type 3 inactivated - 32D.U., Bordetella Pertussis Antigens: toxoid - 25mcg, Bordetella Pertussis Antigens: filamentous haemagglutinin - 25mcg Injectable suspension 1,628,737 L.L
D08AC52 CYTEAL Solution Antiseptique G Chlorhexidine digluconate - 0.5ml/100ml, Hexamidine - 0.1g/100ml, Chlorocresol - 0.3g/100ml Solution 616,977 L.L
J07CA06 INFANRIX IPV + HIB B Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen(Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg, Tetanus toxoid (Prefilled syringe) - ?40IU, Diphtheria toxoid (Prefilled syringe) - ?30IU, H. Influenza type b polysaccharide(Vial) - 10mcg Injectable dry powder+suspension 3,014,239 L.L
J07CA06 PENTAXIM B Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen (Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg, Tetanus toxoid (Prefilled syringe) - ?40IU, Diphtheria toxoid (Prefilled syringe) - ?30IU, H. Influenza type b polysaccharide(Vial) - 10mcg Injectable dry powder+suspension 2,558,676 L.L
J07CA09 INFANRIX HEXA B Diphteria toxoid purified (Prefilled syringe) - ?30IU/0.5ml, Tetanus toxoid purified (prefilled syringe) - ?40IU/0.5ml, Bordetella pertussis antigen (Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg/0.5ml, Poliomyelitis virus type 1 antigen (prefilled syringe) - 40D.U./0.5ml, Poliomyelitis virus type 2 antigen(prefilled syringe) - 8D.U./0.5ml, Poliomyelitis virus type 3 antigen (prefilled syringe) - 32D.U./0.5ml, HBs Antigen (prefilled syringe) - 10mcg/0.5ml, H. Influenza type b polysaccharide (Vial) - 10mcg/0.5ml Injectable suspension 4,230,416 L.L
A06AD61 SOFLAX G Lactose - less than 6g/100ml, Galactose - less than 11g/100ml, Lactulose - 67g/100ml Solution 258,018 L.L
J07CA09 HEXAXIM BioTech Diphteria Toxoid - ?20IU/0.5ml, Tetanus toxoid - ?40IU/0.5ml, Bordetella Pertussis Antigens: toxoid - 25mcg/0.5ml, Bordetella Pertussis Antigens: filamentous haemagglutinin - 25mcg/0.5ml, Polio virus inactivated type 1 (Mahoney strain) - 40D antigen units/0.5ml, Polio virus inactivated type 2 (MEF-I strain) - 8D antigen units/0.5ml, Polio virus inactivated type 3 (Saukett strain) - 32D antigen units/0.5ml, Hepatitis B, surface antigen - 10mcg/0.5ml, H. Influenza type b polysaccharide1 ,2 - 12mcg/0.5ml, 1 conjugated to tetanus protein - 22-36mcg, 2 adsorbed on aluminium hydroxide hydrated, Al+++ - 0.6mg Injectable suspension 4,462,901 L.L
A06AD65 FORTRANS POUDRE POUR SOLUTION BUVABLE B Potassium chloride - 0.750g, Sodium chloride - 1460g, Sodium bicarbonate - 1680g, Sodium sulfate anhydrous - 5700g, Macrogol 4000 - 64.000g Powder for solution 927,251 L.L
J07CA11 DIPHTHERIA, TETANUS,PERTUSSIS, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE B Diphteria Toxoid1 - ?25Lf (?30IU)/0.5ml, Tetanus toxoid1 - ?2.5Lf (?40IU)/0.5ml, Bordetella pertussis (Whole cell) - ?16OU (?4.0IU)/0.5ml, HBs Antigen (r DNA)1 - ?10mcg/0.5ml, H. Influenza type b, purified capsular polysaccharide2 - 10mcg/0.5ml, 1 adsorbed on aluminium phosphate, Al+++ - ?1.25mg , 2 conjugated to tetanos toxoid carrier protein - Injectable suspension 1,515,854 L.L
A06AD65 MOVICOL B Potassium chloride - 0.0466g, Sodium chloride - 0.3507g, Sodium bicarbonate - 0.1785g, Macrogol 3350 - 13.125g Powder for solution 853,340 L.L
A06AD65 MOVICOL PEDIATRIC PLAIN B Potassium chloride - 23.3mg, Sodium chloride - 175.4mg, Sodium bicarbonate - 89.3mg, Macrogol 3350 - 6.563g Powder for solution 624,887 L.L
A06AG11 MINILAX G Sodium citrate (dihydrate) - 900mg/10ml, Sodium lauryl sulfate - 150mg/10ml, Glycerol - 1200mg/10ml, Sorbic acid - 10mg/10ml, Sorbitol - 9.96mg/10ml Solution 474,824 L.L
A06AX01 SUPPOSITOIRE GLYCERINE ENFANT G Glycerol Stearate USP - Suppository 179,179 L.L
S01CA01 API-TOBRASON G Dexamethasone - 1mg/ml, Tobramycin - 3mg/ml Drops suspension 294,302 L.L
A06AX01 SUPPOSITOIRE GLYCERINE ENFANT G Glycerol Stearate USP - Suppository 179,179 L.L
D10AD01 RETACNYL - 0.05 % G Tretinoin - 0.05% Cream 584,571 L.L
S01CA01 CO-AVAZIR G Tobramycin - 0.3%, Dexamethasone - 0.1% Drops suspension 193,513 L.L
    ...
    179
Sitemap
© Copyrights reserved to Ministry of Public Health 2025